Solid tumor testing is a procedure used to evaluate primary tumor and determine extent/location of any metastases. The tumor testing in turn allows effective treatment options to be considered so that the spread of cancerous cells can be avoided. Increase in incidence of cancer and rise in funding support by various organizations drive the market. Moreover, growth in demand for personalized medicine also propels the market. However, stringent regulatory approval procedure restricts the market growth. Get Sample Report
The global solid tumor testing market is segmented on the basis of cancer type and region. According to cancer type, the market is divided into breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, and others. By geography, it is analyzed across four regions, namely, North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Stakeholders • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets. • It presents a quantitative analysis from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities. • Extensive analysis of the market assists in understanding the regional trends. • Key players and their strategies are analyzed to understand the competitive outlook of the market.
The key companies of the solid tumor testing market include Abbott Laboratories, Agilent Technologies, 20/20 GeneSystems Inc., Thermo Fisher Scientific, Inc., Avant Diagnostics, Inc., Advanced Cell Diagnostics, Inc., Agena Bioscience, Inc., Bio-Rad Laboratories, Inc., Johnson & Johnson, and Biocare Medical, LLC.